Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 31.6 CNY -0.54% Market Closed
Market Cap: 24.3B CNY
Have any thoughts about
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd?
Write Note
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Current Portion of Long-Term Debt
¥26.2m
CAGR 3-Years
-6%
CAGR 5-Years
85%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Current Portion of Long-Term Debt
¥4.2B
CAGR 3-Years
625%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Current Portion of Long-Term Debt
¥27.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
12%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Current Portion of Long-Term Debt
¥36.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Current Portion of Long-Term Debt
¥68.7m
CAGR 3-Years
-58%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Current Portion of Long-Term Debt
¥179.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
24.3B CNY
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

Intrinsic Value
39.26 CNY
Undervaluation 20%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
26.2m CNY

Based on the financial report for Sep 30, 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Current Portion of Long-Term Debt amounts to 26.2m CNY.

What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
85%

Over the last year, the Current Portion of Long-Term Debt growth was 2 964%. The average annual Current Portion of Long-Term Debt growth rates for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd have been -6% over the past three years , 85% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.